The Latest Breaking News from ZTS

Using the POWR Ratings to power profits on a POWR Pairs trade in Zoetis (ZTS) and Air Products (APD).

The pharmaceutical industry is expected to grow rapidly due to increasing healthcare demand, technological advancements, and rising demand for innovative drugs. Therefore, for portfolio diversification, investors could consider buying fundamentally strong pharmaceutical stocks such as Bayer (BAYRY), Procaps Group (PROC), ACADIA Pharmaceuticals (ACAD), and Zoetis (ZTS). Read more.

Veterinary drugmaker Zoetis Inc. (ZTS) is all set to disclose its fiscal fourth-quarter earnings tomorrow. With the company boasting an impressive track record of consistently surpassing earnings expectations, would it be wise to acquire the shares of ZTS ahead of its earnings? Keep reading to find out….

The pharma industry is experiencing significant growth, fueled by rising demand for personalized medicines, a revolutionary wave of drug development and robust government support. Therefore, it could be wise to consider fundamentally strong pharma stocks Zoetis (ZTS), Bristol-Myers Squibb (BMY), and Teva Pharmaceutical Industries (TEVA) to guard your portfolio. Read…

The pharmaceutical industry is anticipated to thrive as demand grows and technology advances. However, given the macroeconomic uncertainties, let us analyze leading pharma stocks Zoetis (ZTS), Verano Holding (VRNOF), Canopy Growth (CGC) and SNDL (SNDL) to identify whether they are a Buy, Hold, or Sell. Read on.

The pharmaceutical industry is expected to grow rapidly due to rising global medical needs and technological advancements. With the industry expected to thrive in the coming years, it could be wise to buy Zoetis (ZTS), AstraZeneca (AZN) and Taro Pharmaceutical (TARO) for steady returns. Read more.

The pharmaceutical industry is evolving with changing consumer behavior, rapid adoption of digital solutions, and global expansion. Hence, fundamentally strong pharma stocks Zoetis (ZTS), Wave Life Sciences (WVE), and Johnson & Johnson (JNJ) might be solid investments now. Read more….

Looking for analysts' favorite stock picks in a traditionally defensive sector, with solid dividend payments to help boost your returns? Here's a look at three stocks for income investors to consider at current levels.

Pfizer (PFE) is grappling with financial difficulties and declining performance. Yet, with growing pharmaceutical demand and industry advancements, robust pharma stocks Zoetis (ZTS), Horizon Therapeutics (HZNP), and Novartis (NVS) appear as more promising buys this month. Read on.

With the rising prevalence of chronic diseases, the demand for pharmaceutical products is anticipated to rise. Therefore, investors could consider buying three fundamentally robust pharma stocks, Eli Lilly and Company (LLY), Zoetis (ZTS), and Taro Pharmaceutical Industries (TARO), which are gaining traction among institutional investors this month. Learn more….

September S&P 500 futures (ESU23) are down -0.45%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.49% this morning as fresh worries about China’s economic rebound and the state of U.S. banks weighed on sentiment.